



AJJ MEDTECH HOLDINGS LIMITED
(Company Registration No. 198403368H)
(Incorporated in the Republic of Singapore)

CESSATION OF CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR AND APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR

1. Introduction

The Board of Directors (the “**Board**”) of AJJ Medtech Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce:

- the cessation of Ms Zhao Xin (“**Ms Zhao**”) as Chief Executive Officer (“**CEO**”) and Executive Director of the Company; and
- the appointment of Dr Tan Wei Jie (“**Dr Tan**”) as Chief Executive Officer and Executive Director of the Company,

both with effect from 15 May 2026.

2. Cessation of Ms Zhao Xin as Chief Executive Officer and Executive Director

Ms Zhao will step down from her roles as Chief Executive Officer and Executive Director of the Company with effect from 15 May 2026.

The Board wishes to place on record its sincere appreciation to Ms Zhao for her leadership and significant contributions during her tenure. Under her leadership, the Group has:

- strengthened its corporate governance and internal control framework;
- advanced and established an integrated healthcare technology platform; and
- established foundational capabilities across medical technology, digital healthcare and platform-based development.

Ms Zhao has been an integral part of the Company’s leadership development framework. Upon graduating from Nanyang Technological University, she joined the Group and underwent continuous and structured leadership development under the Group’s talent development framework, including the completion of executive leadership programmes at Harvard Business School, reflecting the Group’s long-term commitment to human capital development, structured leadership succession planning and the development of globally-oriented leadership capabilities.

During her approximately six-year tenure, Ms Zhao, together with the Board, played a key role in shaping and embedding a corporate culture centred on “fairness, transparency, professionalism and integrity”.

The Board confirms that there are no disagreements between Ms Zhao and the Board, and that there are no matters relating to her cessation that need to be brought to the attention of shareholders of the Company.

3. Continued Engagement of Ms Zhao Xin

To ensure strategic continuity and retention of institutional knowledge, Ms Zhao will continue to support the Company in a **strategic and senior advisory capacity**. This role will be non-executive in nature and will not involve participation in management decision-making or day-to-day operations, and may include participation in strategic discussions, where appropriate (without voting rights).

4. Appointment of Dr Tan Wei Jie as Chief Executive Officer and Executive Director

The Board is pleased to announce the appointment of Dr Tan Wei Jie as Chief Executive Officer and Executive Director of the Company with effect from 15 May 2026.

Dr Tan is a Singapore citizen and holds a Doctor of Philosophy (PhD) in Nanomedicine and Materials Science from Nanyang Technological University. Upon graduation, he joined the Group and was selected into the Company's professional leadership development programme. He has since undergone approximately four years of structured leadership development under the Group's talent development framework, progressing within the organisation and taking on increasing levels of management responsibility.

During his tenure, Dr Tan has:

- secured and managed institutional contracts contributing to the establishment of recurring revenue streams for the Group;
- led and optimised the Group's supply chain management (SCM), significantly enhancing operational efficiency and cost discipline; and
- played a key role in aligning commercial strategy with operational execution to support the Group's sustainable growth.

As a representative of a new generation of management, Dr Tan demonstrates strong forward-looking awareness and adaptability in relation to developments in robotics, artificial intelligence and emerging healthcare technologies.

The Board is of the view that Dr Tan is well-positioned to lead the Group into its next phase of execution-driven growth, commercial scaling and enhanced operational discipline, with a focus on translating platform capabilities into repeatable and scalable execution outcomes.

5. Rationale for the Leadership Transition

This leadership transition reflects the Group's progression from platform development to execution and commercialisation.

The Board believes that the appointment of Dr Tan will further strengthen the Group's ability to:

- deliver near-term revenue growth;
- execute on its established strategic initiatives; and
- enhance operational and financial discipline.

The Board further believes that appointing a new generation of leadership as Chief Executive Officer will enhance the Group's learning agility, adaptability and execution capability in the fields of robotics, artificial intelligence and emerging healthcare technologies, thereby positioning the Group to better capture future industry opportunities.

In this context, the Board is of the view that the Group's next phase of growth will be driven by its ability to translate technology and platform capabilities into repeatable and scalable execution models.

The Group remains committed to leadership development and succession planning, and will continue to strengthen its talent pipeline to support its long-term growth as a healthcare technology platform.

Further details in relation to the cessation of Ms Zhao and the appointment of Dr Tan pursuant to Rule 704(7) of the SGX-ST Listing Manual will be released separately on the same date.

6. Board Statement

The Board remains confident in the Group's long-term prospects and believes that this leadership transition will further strengthen the Group's execution capabilities and enhance its ability to deliver sustainable long-term value to shareholders.

BY ORDER OF THE BOARD

Dr Zhang Jian
Chairman and Executive Director

04 May 2026

*This document has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Centre, Singapore 068914.